Kiniksa Pharmaceuticals raises 2026 ARCALYST net product revenue guidance to $980–$995 million after Q2 net income of $25.4 million
https://finviz.com/stock?t=KNSA&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.